Notícias e Atividades da Voyager Therapeutics

Voyager Therapeutics é uma das ...

• Russell 3000;
• TOB Iconic 10,000.

Voyager Therapeutics é uma empresa listada sob o símbolo VYGR (US).

Veja o organograma con seus 19 executivos principais

Biografias mais buscadas da Voyager Therapeutics

• Alfred Sandrock, Chief Executive Officer and Director
• Michael Higgins, Chairman of the Board
• Steven Hyman, Director

Criar um alerta
para seguir os movimentos de executivos da Voyager Therapeutics.

Voyager Therapeutics possui 2.350 concorrentes concorrentes Astellas Gene Therapies (Estados Unidos), Eurofins (Luxemburgo) e Lonza (Suíça).

Popular M&A news in Biotecnologia

• Sirius Therapeutics acaba de anunciar uma arrecadação de fundos de 50 milhões de dólares. (publicado em 16 de junho de 2025).
• BioNTech has announced the acquisition of CureVac  (publicado em 12 de junho de 2025).
• SpliceBio acaba de anunciar uma arrecadação de fundos de 135 milhões de dólares. (publicado em 11 de junho de 2025).

Outros contatos sugeridos na indústria do Biotecnologia

• Sandra Smith - Senior Vice President, Clinical Solutions & Strategic Partnerships da WIRB-Copernicus Group
• Jasbir Seehra - Chief Executive Officer and Chairman of the Board da Keros Therapeutics
• Deepika Verma - Associate Director of Data Science and Digitalization da Wheeler Bio

Saiba mais sobre a indústria do Biotecnologia

Últimos comunicados de imprensa de Voyager Therapeutics

• Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference | Voyager Therapeutics Inc.
• Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication | Voyager Therapeutics Inc.
• Voyager Reports First Quarter 2025 Financial and Operating Results | Voyager Therapeutics Inc.
• Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting | Voyager Therapeutics Inc.
• Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025 | Voyager Therapeutics Inc.
• Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results | Voyager Therapeutics Inc.
• Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease | Voyager Therapeutics Inc.
• Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast | Voyager Therapeutics Inc.
• Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences | Voyager Therapeutics Inc.
• Voyager Provides Update on SOD1 ALS Gene Therapy Program | Voyager Therapeutics Inc.
• View more press releases Close

Redes sociais sobre Voyager Therapeutics

• Voyager Therapeutics na Wikipedia, Google News e Yahoo Finance
• Voyager Therapeutics na LinkedIn, Twitter e YouTube